Product Code: ETC6194661 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The mRNA therapeutics market in Australia is expanding rapidly, propelled by advancements in gene-based treatments for cancer, rare diseases, and infectious diseases. Startups and established pharmaceutical companies are heavily investing in R&D to develop novel mRNA therapies. The Australian government and academic institutions are playing pivotal roles through funding initiatives and clinical research support. Regulatory streamlining and incentives for biotech innovation further stimulate the growth of this sector, with several candidates already in the clinical trial pipeline.
Australia`s mRNA therapeutics market is evolving rapidly, with applications extending beyond infectious diseases into oncology, rare genetic disorders, and immunology. Biotech startups and established pharmaceutical companies are leveraging mRNA platforms for personalized medicine and targeted therapies. Government grants and venture capital funding are supporting innovation, while regulatory bodies are streamlining approval processes. Collaborations with global players are helping Australian firms access advanced technologies and clinical trial networks.
In Australia, the mRNA therapeutics market struggles with high research and development costs and the uncertainty surrounding long-term efficacy and safety of mRNA-based treatments. Intellectual property issues and patent disputes may impede innovation and collaboration. Moreover, the absence of a large number of clinical trials and limited local biomanufacturing capacity restricts rapid progress in this field. Regulatory frameworks also need to evolve to keep pace with the fast-moving mRNA therapeutics landscape, which is currently a bottleneck for timely approvals.
With mRNA therapeutic applications expanding across cancer, genetic diseases, and autoimmune disorders, Australia provides fertile ground for venture capital and institutional investment. Biotech startups with a strong R&D pipeline and IP assets are particularly appealing. There are also investment opportunities in platform technology companies that enable scalable and targeted mRNA delivery systems. Collaborations between investors and research institutions for clinical trial funding and regulatory navigation are proving mutually beneficial.
Government policies affecting the mRNA therapeutics market are mainly focused on regulating new treatments and therapies through the TGA. The Australian government has created frameworks to support the development of innovative therapies, including faster regulatory pathways for breakthrough treatments. Policies around clinical trial funding and support for biotech start-ups through organizations like AusIndustry help foster an innovation ecosystem. However, the lengthy approval process and cost of regulatory compliance remain challenges. Additionally, there is ongoing dialogue about pricing and reimbursement policies under the Pharmaceutical Benefits Scheme (PBS), which could influence the adoption of new mRNA therapeutics in the public healthcare system.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia mRNA Therapeutics Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia mRNA Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Australia mRNA Therapeutics Market - Industry Life Cycle |
3.4 Australia mRNA Therapeutics Market - Porter's Five Forces |
3.5 Australia mRNA Therapeutics Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Australia mRNA Therapeutics Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Australia mRNA Therapeutics Market Revenues & Volume Share, By End use, 2021 & 2031F |
4 Australia mRNA Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia mRNA Therapeutics Market Trends |
6 Australia mRNA Therapeutics Market, By Types |
6.1 Australia mRNA Therapeutics Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Australia mRNA Therapeutics Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Australia mRNA Therapeutics Market Revenues & Volume, By Prophylactic, 2021- 2031F |
6.1.4 Australia mRNA Therapeutics Market Revenues & Volume, By Therapeutic, 2021- 2031F |
6.2 Australia mRNA Therapeutics Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Australia mRNA Therapeutics Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.2.3 Australia mRNA Therapeutics Market Revenues & Volume, By Oncology, 2021- 2031F |
6.2.4 Australia mRNA Therapeutics Market Revenues & Volume, By Rare Genetic Diseases, 2021- 2031F |
6.2.5 Australia mRNA Therapeutics Market Revenues & Volume, By Respiratory Diseases, 2021- 2031F |
6.2.6 Australia mRNA Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia mRNA Therapeutics Market, By End use |
6.3.1 Overview and Analysis |
6.3.2 Australia mRNA Therapeutics Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.3.3 Australia mRNA Therapeutics Market Revenues & Volume, By Research Organizations, 2021- 2031F |
6.3.4 Australia mRNA Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia mRNA Therapeutics Market Import-Export Trade Statistics |
7.1 Australia mRNA Therapeutics Market Export to Major Countries |
7.2 Australia mRNA Therapeutics Market Imports from Major Countries |
8 Australia mRNA Therapeutics Market Key Performance Indicators |
9 Australia mRNA Therapeutics Market - Opportunity Assessment |
9.1 Australia mRNA Therapeutics Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Australia mRNA Therapeutics Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Australia mRNA Therapeutics Market Opportunity Assessment, By End use, 2021 & 2031F |
10 Australia mRNA Therapeutics Market - Competitive Landscape |
10.1 Australia mRNA Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Australia mRNA Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |